Arcus Biosciences, Inc. (RCUS): Price and Financial Metrics
RCUS Stock Summary
- RCUS's went public 3.1 years ago, making it older than just 9.25% of listed US stocks we're tracking.
- RCUS's price/sales ratio is 29.31; that's higher than the P/S ratio of 92.33% of US stocks.
- As for revenue growth, note that RCUS's revenue has grown 416.78% over the past 12 months; that beats the revenue growth of 98.35% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Arcus Biosciences Inc are SYRS, NTLA, MORF, AUTL, and ANAB.
- Visit RCUS's SEC page to see the company's official filings. To visit the company's web site, go to www.arcusbio.com.
RCUS Stock Price Chart Interactive Chart >
RCUS Price/Volume Stats
|Current price||$31.65||52-week high||$42.36|
|Prev. close||$32.06||52-week low||$16.69|
|Day high||$32.35||Avg. volume||528,193|
|50-day MA||$33.82||Dividend yield||N/A|
|200-day MA||$27.34||Market Cap||2.24B|
Arcus Biosciences, Inc. (RCUS) Company Bio
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is based in Hayward, California.
RCUS Latest News Stream
|Loading, please wait...|
RCUS Latest Social Stream
View Full RCUS Social Stream
Latest RCUS News From Around the Web
Below are the latest news stories about Arcus Biosciences Inc that investors may wish to consider to help them evaluate RCUS as an investment opportunity.
The following slide deck was published by Arcus Biosciences, Inc. in conjunction with this event....
Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented progression-free survival (PFS) and overall survival (OS) data in patients with advanced metastatic colorectal cancer (mCRC) from the ARC-3 study at the 2021 American Association for Cancer Research (AACR) Annual Meeting. ARC-3 was a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study that evaluated the safety, tolerability, PK and early clinical activity of etrumadenant, the first dual adenosine A2a/A2b receptor antagonist in the clinic, in subjects with mCRC.
Mizuho Securities Stick to Their Buy Rating for Arcus Biosciences Inc
Arcus Biosciences, Inc. ( NYSE:RCUS ) shareholders will have a reason to smile today, with the analysts making...
Shareholders of Arcus Biosciences, Inc. ( NYSE:RCUS ) will be pleased this week, given that the stock price is up 11...
RCUS Price Returns
Continue Researching RCUSWant to see what other sources are saying about Arcus Biosciences Inc's financials and stock price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!